Skip to main content

Xuefang Cao, PhD

Academic Title:

Associate Professor

Primary Appointment:

Microbiology and Immunology

Administrative Title:

Co-Leader of the Tumor Immunology & Immunotherapy Program (TII)

Location:

655 W Baltimore Street, BRB 10-045

Phone (Primary):

410-706-8452

Education and Training

Hebei Medical University, Shijiazhuang, China, MD, Medicine, 1994

Peking Union Medical College, Beijing, China, MS, Pharmacology, 1999

University of Florida, Gainesville, Florida, PhD, Cancer Biology, 2003

Washington University, Saint Louis, Missouri, Postdoctoral Fellow, Cancer Immunology, 2008

Biosketch

The scientific interests of our lab have been directed towards understanding the complexities of T cell biology and how T cells contribute to tumor immunity and transplantation immunity. To this end, we focus on investigating the cellular and molecular mechanisms governing T cell development, differentiation, activation, and effector function. Specifically, we are interested in the co-stimulatory and co-inhibitory signals, sympathetic neurotransmitters, and cytotoxic pathways that are involved in the interactions among T cells, other immune cells and cancer cells in the setting of immune homeostasis, tumor progression and immune reconstitution after allogeneic hematopoietic cell transplantation. Our long-term goal is to develop immune-based therapies that are safe and effective for cancer patients. Currently we are studying cancer patients and mouse models, including syngeneic tumor models and allogeneic hematopoietic cell transplantation, to develop T cell-based and regulatory pathway-targeted cancer immunotherapies.

Research/Clinical Keywords

Cancer immunology and immunotherapy, transplantation immunology, T cell biology, allogeneic hematopoietic cell transplantation (allo-HCT), graft-versus-host disease (GVHD)

Highlighted Publications

Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms D, Ley TJ.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearanceImmunity. 2007 Oct; 27(4):635-46. PMID: 17919943

O'Neill RE, Du W, Mohammadpour H, Alqassim E, Qiu J, Chen G, McCarthy PL, Lee KP, Cao X.    T Cell-Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses.  J Immunol. 2017 Nov 15;199(10):3700-3710. PMID: 29046346

Mohammadpour H, O'Neil R, Qiu J, McCarthy PL, Repasky EA, Cao X.  Blockade of Host β2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs.  J Immunol. 2018 Apr 1;200(7):2479-2488.  PMID: 29445008

Ciavattone NG, Wu L, O'Neill R, Qiu J, Davila E, Cao X. MyD88 co-stimulation in donor CD8+ T cells enhances the graft-versus-tumor effect in murine hematopoietic cell transplantation.  J Immunol. 2021 Feb 15;206(4):892-903. PMID: 33408257

Tibbs E, Kandy RRK, Jiao D, Wu L, Cao X. Murine regulatory T cells utilize granzyme B to promote tumor metastasis. Cancer Immunol Immunother. 2023 Sep;72(9):2927-2937. doi: 10.1007/s00262-023-03410-w. Epub 2023 Feb 24. PubMed PMID: 36826509; PubMed Central PMCID: PMC10690887.

Puppala ER, Wu L, Fan X, Cao X. CD27 signaling inhibits tumor growth and metastasis via CD8 + T cell-independent mechanisms in the B16-F10 melanoma model. Cancer Immunol Immunother. 2024 Aug 6;73(10):198. doi: 10.1007/s00262-024-03780-9. PMID: 39105866

Additional Publication Citations

Awards and Affiliations

Grants and Contracts

×